Weight regain after stopping semaglutide

What happened when the trial ended

The STEP 1 extension answers an important question that the before-and-after photos leave out: what happened once the treatment period was over? The original trial enrolled adults with overweight or obesity who did not have diabetes. At week 68, the study medication and the structured lifestyle intervention were withdrawn. A subset of participants was then followed for another year.¹

That detail about lifestyle support matters. This was not a clean comparison between stopping a drug and continuing the same support without it. Both parts of the intervention ended. The extension can describe what happened afterward, but it cannot tell us how much regain would have occurred if the same support had continued.

The published extension included 327 participants, rather than everyone from the original trial. Its analyses were exploratory. That makes it useful evidence about the period after treatment, with a narrower scope than a new randomized trial designed to test a stopping strategy.¹

What the weight figures mean

In the semaglutide group, mean weight loss during treatment was 17.3% from baseline. Over the following year, participants regained 11.6 percentage points. At the end of the extension, the reported mean net loss from the original baseline was 5.6%. The investigators summarized this as regaining two-thirds of the previous loss.¹

These are group averages. The paper does not say that every participant followed the average, or that every person who stops semaglutide will regain the same share. An average is useful for planning a conversation; it is a poor substitute for an individual follow-up plan.

There are also two different denominators in the headline. Weight lost during treatment is expressed against starting body weight. The share regained is expressed against the weight previously lost. Confusing those denominators makes the result sound much more dramatic than the study actually reported.

The placebo group had a different starting point: its mean loss during treatment was 2.0%, followed by regain of 1.9 percentage points. Its reported net loss at the end was 0.1%. These figures help describe the trial; they are not a comparison between stopping semaglutide and following a particular diet.¹

What happened to the other health markers

The researchers also reported that most improvements in cardiometabolic measures moved back toward baseline after withdrawal. This is another reason a maintenance conversation should cover more than the number on the scale. If a clinician is following a health measure for you, ask how that measure will be monitored if treatment changes.¹

Do not use the extension to decide that a medication prescribed for diabetes, kidney disease or cardiovascular risk is no longer needed once a weight goal is reached. The reason for the prescription is a separate question from the amount of weight lost. This study enrolled people without diabetes and was not a trial of stopping treatment for those other indications.

Does tapering prevent regain?

This study did not randomize people to different tapering schedules, lower maintenance doses or a switch to another medicine. It therefore cannot establish that one of those approaches prevents regain. A precise taper copied from a post or a clinic advertisement is not made evidence-based by placing the STEP 1 citation beside it.

If stopping is being considered, the useful questions are practical: Why are we stopping? What outcomes are we following? Who will review a change in weight or other health measures? What happens if coverage returns or the reason for stopping changes? Your prescriber should answer the treatment questions, and the provider should explain its follow-up arrangements.

The cost question deserves its own answer too. A program that is affordable only for an introductory period may create a decision point long before treatment goals are settled. Before committing to a prepaid plan, ask what care remains available when the term ends and whether a clinician visit is included. Those are service questions, not a reason to improvise a dosing plan. Our Hims & Hers review explains why stopping medication and stopping membership billing are separate steps; that distinction belongs in a financial plan for ongoing care.

How to use the finding

The most useful takeaway is that reaching a target weight and planning to maintain it are different decisions. The extension supports taking the second decision seriously. It does not show that you have failed if weight returns, and it does not predict your result.

Bring the actual reason you may stop to the visit: cost, side effects, a new health issue, pregnancy planning or a preference to change treatment. Ask the clinician to distinguish a temporary interruption from a longer-term plan. A plan for either should be specific to the product and the reason it was prescribed.